Levels of circulating selenoprotein P, fibroblast growth factor (FGF) 21 and FGF23 in relation to the metabolic syndrome in young children

International Journal of Obesity

Volumn 38, Issue 12, 2014, Pages 1497-1502

  Ko, B J ^a,b   Kim, S M ^b   Park, K H ^a,c   Park, H S ^d   Mantzoros, C S ^a,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Korea University College of Medicine   (South Korea)

^c Hallym University Sacred Heart Hospital   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

child; fibroblast growth factor 21; fibroblast growth factor 23; metabolic syndrome; selenoprotein P

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SELENOPROTEIN P; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASSESSMENT OF HUMANS; BLOOD CHEMISTRY; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CARDIOMETABOLIC RISK; CHILD; CHILDHOOD OBESITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERTENSION; HYPOCHOLESTEROLEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHOOL CHILD; SCHOOL HEALTH SERVICE; SERUM; TREND STUDY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; DISEASE PREDISPOSITION; GENETICS; HEALTH BEHAVIOR; METABOLISM; MOTOR ACTIVITY; QUESTIONNAIRE; SLEEP; SOUTH KOREA;

BLOOD GLUCOSE; BODY MASS INDEX; CHILD; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; FIBROBLAST GROWTH FACTORS; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MOTOR ACTIVITY; QUESTIONNAIRES; REPUBLIC OF KOREA; RISK FACTORS; SCHOOL HEALTH SERVICES; SELENOPROTEIN P; SLEEP; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84927176428     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2014.45     Document Type: Article

References (41)

1. Balkau B, CharLes MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443
2. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-Analysis of prospective cohort studies. Eur J EpiDemiol 2010; 25: 375-384
3. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-Analysis. J Am Coll Cardiol 2010; 56: 1113-1132
4. Tailor AM, Peeters PH, Norat T, Vineis P, Romaguera D. An update on the prevaLence of the metabolic syndrome in children and adoLescents. Int J Pediatr Obes 2010; 5: 202-213
5. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multipLe cardiovascular risk factors and atheroscLerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338: 1650-1656
6. Iannuzzi A, Licenziati MR, Acampora C, Renis M, Agrusta M, Romano L et al. Carotid artery stiffness in obese children with the metabolic syndrome. Am J Cardiol 2006; 97: 528-531
7. Chen W, Srinivasan SR, Li S, Xu J, Berenson GS. Metabolic syndrome variabLes at low Levels in childhood are beneficially associated with adulthood cardiovascular risk: the Bogalusa Heart Study. Diabetes Care 2005; 28: 126-131
8. Burk RF, Hill KE, MotLey AK. Plasma seLenium in specific and non-specific forms. Biofactors 2001; 14: 107-114
9. Akesson B, BelLew T, Burk RF. Purification of seLenoprotein P from human plasma. Biochim Biophys Acta 1994; 1204: 243-249
10. Burk RF, Hill KE. SeLenoprotein P: an extracellular protein with unique physical characteristics and a roLe in seLenium homeostasis. Annu Rev Nutr 2005; 25: 215-235
11. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S et al. A liver-Derived secretory protein, seLenoprotein P, causes insulin resistance. Cell Metab 2010; 12: 483-495
12. Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG et al. Serum seLenoprotein P Levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atheroscLerosis. J Clin Endocrinol Metab 2011; 96: E1325-E1329
13. Speckmann B, Walter PL, Alili L, Reinehr R, Sies H, Klotz LO et al. SeLenoprotein P expression is controlLed through interaction of the coactivator PGC-1alpha with FoxO1a and hepatocyte nucLear factor 4alpha transcription factors. Hepatology 2008; 48: 1998-2006
14. Jackson MI, Cao J, Zeng H, Uthus E, Combs GF Jr. S-ADenosylmethionineDepenDent protein methylation is required for expression of seLenoprotein P and gluconeogenic enzymes in HepG2 human hepatocytes. J Biol Chem 2012; 287: 36455-36464
15. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8: 235-253
16. Kralisch S, Fasshauer M. Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease. Curr Opin Clin Nutr Metab Care 2011; 14: 354-359
17. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators-A critical appraisal. Cell Metab 2012; 16: 693-705
18. Reinehr T, WoelfLe J, Wunsch R, Roth CL. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 2012; 97: 2143-2150
19. Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipiDemia in two inDepenDent cohorts of elDerly individuals. ArterioscLer Thromb Vasc Biol 2011; 31: 219-227
20. Wojcik M, DoLezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB. FGF23 contributes to insulin sensitivity in obese adoLescents-preliminary results. Clin Endocrinol 2012; 77: 537-540
21. Choi KM, Yannakoulia M, Park MS, Cho GJ, Kim JH, Lee SH et al. Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the Development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr 2011; 93: 19-26
22. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA moDeling. Diabetes Care 2004; 27: 1487-1495
23. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. PrevaLence of a metabolic syndrome phenotype in adoLescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr AdoLesc Med 2003; 157: 821-827
24. Committee on Health and Statistics, Korean Pediatrics Society. Korean physical growth standards for children and adoLescents. Korean Pediatrics Society: Seoul, Korea, 2007
25. Kabuyama Y, Oshima K, Kitamura T, Homma M, Yamaki J, Munakata M et al. Involvement of seLenoprotein P in the regulation of redox balance and myofibroblast viability in idiopathic pulmonary fibrosis. Genes Cells 2007; 12: 1235-1244
26. Steinbrenner H, Alili L, Bilgic E, Sies H, Brenneisen P. Involvement of seLenoprotein P in protection of human astrocytes from oxidative damage. Free Radic Biol Med 2006; 40: 1513-1523
27. Zhang Y, Chen X. Reducing seLenoprotein P expression suppresses adipocyte differentiation as a result of increased preadipocyte inflammation. Am J Physiol Endocrinol Metab 2011; 300: E77-E85
28. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF et al. Effects of long-term seLenium suppLementation on the inciDence of type 2 diabetes: a randomized trial. Ann Intern Med 2007; 147: 217-223
29. KLein EA, Thompson IM Jr, Tangen CM, CrowLey JJ, Lucia MS, Goodman PJ et al. Vitamin E and the risk of prostate cancer: the SeLenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-1556
30. Ezaki O. The insulin-like effects of seLenate in rat adipocytes. J Biol Chem 1990; 265: 1124-1128
31. Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfield DL, Gladyshev VN. Both maximal expression of seLenoproteins and seLenoprotein Deficiency can promote Development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal 2011; 14: 2327-2336
32. Rayman MP, Stranges S. EpiDemiology of seLenium and type 2 diabetes: Can we make sense of it? Free Radic Biol Med 2013; 65: 1557-1564
33. Choi HY, Hwang SY, Lee CH, Hong HC, Yang SJ, Yoo HJ et al. Increased seLenoprotein p Levels in subjects with visceral obesity and nonalcoholic fatty liver disease. Diabetes Metab J 2013; 37: 63-71
34. Mao J, Teng W. The relationship between seLenoprotein P and glucose metabolism in experimental studies. Nutrients 2013; 5: 1937-1948
35. Choi Y, Kim J, Lee H-S, Kim C-i, Hwang IK, Park HK et al. SeLenium content in representative Korean foods. J Food Compost Anal 2009; 22: 117-122
36. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789
37. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F et al. Serum FGF21 Levels are increased in obesity and are inDepenDently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-1253
38. Srinivasan SR, Frontini MG, Berenson GS. Longitudinal changes in risk variabLes of insulin resistance syndrome from childhood to young adulthood in offspring of parents with type 2 diabetes: the Bogalusa Heart Study. Metabolism 2003; 52: 443-450
39. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 Deficient mice. Matrix Biol 2007; 26: 75-84
40. Majumdar V, Christopher R. Association of exonic variants of Klotho with metabolic syndrome in Asian Indians. Clin Chim Acta 2011; 412: 1116-1121
41. Streicher C, Zeitz U, Andrukhova O, Rupprecht A, Pohl E, Larsson TE et al. Long-term Fgf23 Deficiency does not influence aging, glucose homeostasis, or fat metabolism in mice with a nonfunctioning vitamin D receptor. Endocrinology 2012; 153: 1795-1805.